REDCLOUD BIO
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER 2022-08-29 19:30
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH 2022-04-07 19:47
REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER 2022-03-02 17:27
1